#BPA: have flawed analytical techniques compromised risk assessments?

Experimental and epidemiological studies provide compelling evidence of a causal link between increasing exposure to endocrine-disrupting chemicals (environmental contaminants with the potential to perturb the development and function of the endocrine system) and increases in non-communicable diseases, including most aspects of metabolic syndrome..

..By virtue of extensive research attention, bisphenol A (BPA) has become the so-called poster child for endocrine-disrupting chemicals.

..Experimental data suggest BPA can affect a variety of endocrine signalling pathways, including those mediated by oestrogens, androgens, progestins, and thyroid hormone.3 Exposure during gestation has been linked to changes in a wide array of developing tissues, with corresponding postnatal effects on growth, metabolism, behaviour, fertility, and cancer risk..

CLARITY data provide evidence of significant adverse effects at the lowest dose examined (2Β·5 ΞΌg/kg per day), far lower than the lowest observed adverse effect level (5000 ΞΌg/kg per day) used to establish the tolerable daily intake for BPA. However, based on the assumption that human exposure to BPA is negligible, the US Food and Drug Administration (FDA) has not taken into account the adverse low dose effects in CLARITY data and many other studies..